Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC014723 | Panoply™ Human SMARCA2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC014723 | Panoply™ Human SMARCA2 Over-expressing Stable Cell Line | Inquiry |
| CSC-RT1565 | Human SMARCA2 Knockout Cell Line-HeLa | Inquiry |
| CLKO-1412 | SMARCA2 KO Cell Lysate-HeLa | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD15132Z | Human SMARCA2 adenoviral particles | Inquiry |
| LV26082L | human SMARCA2 (NM_003070) lentivirus particles | Inquiry |
| LV26083L | human SMARCA2 (NM_139045) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH413088 | shRNA set against Human SMARCA2 (NM_003070.3) | Inquiry |
| SHH413092 | shRNA set against Mouse SMARCA2 (NM_011416.2) | Inquiry |
| SHH413096 | shRNA set against Rat SMARCA2 (NM_001004446.1) | Inquiry |
| SHL015622 | shRNA set against Human SMARCA2(NM_003070.3) | Inquiry |
| SHL015624 | shRNA set against Rat Smarca2(NM_001004446.1) | Inquiry |
| SHL015642 | shRNA set against Mouse Smarca2(NM_026003.2) | Inquiry |
| SHL015660 | shRNA set against Human SMARCA2(NM_139045.2) | Inquiry |
| SHL015678 | shRNA set against Human SMARCA2(NM_003070.3) | Inquiry |
| SHL015762 | shRNA set against Mouse Smarca2(NM_011416.2) | Inquiry |
| SHW005639 | shRNA set against Chicken SMARCA2 (NM_205139) | Inquiry |
| SHW009806 | shRNA set against Danio rerio SMARCA2 (NM_001044775) | Inquiry |
| SHW015515 | shRNA set against Danio rerio SMARCA4A (NM_181603) | Inquiry |
| SHW017876 | shRNA set against Danio rerio SMARCA2 (NM_212716) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| MiUTR1R-07558 | SMARCA2 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-10979 | SMARCA2 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-09644 | SMARCA2 miRNA 3'UTR clone | Inquiry |
| MiUTR1H-09643 | SMARCA2 miRNA 3'UTR clone | Inquiry |
| CDFR001439 | Rat Smarca2 cDNA Clone(NM_001004446.1) | Inquiry |
| CDFL012716 | Mouse Smarca2 cDNA Clone(NM_011416.2) | Inquiry |
| CDFH018136 | Human SMARCA2 cDNA Clone(NM_003070.3) | Inquiry |
| CDCH083400 | Mouse Smarca2 ORF clone (NM_011416.2) | Inquiry |
| CDFG008368 | Human SMARCA2 cDNA Clone(NM_139045.2) | Inquiry |
| MiUTR1M-10980 | SMARCA2 miRNA 3'UTR clone | Inquiry |
| CDCR368360 | Rat Smarca2 ORF Clone(NM_001004446.1) | Inquiry |
| CDCH083396 | human SMARCA2 ORF clone (NM_139045.2) | Inquiry |
| CDCH083394 | human SMARCA2 ORF clone (NM_003070.3) | Inquiry |
| CDCB194434 | Rabbit SMARCA2 ORF clone (XM_002708185.2) | Inquiry |
| CDCB179351 | Danio rerio SMARCA2 ORF Clone (NM_212716) | Inquiry |
| CDCB176990 | Danio rerio SMARCA4A ORF Clone (NM_181603) | Inquiry |
| CDCB171281 | Danio rerio SMARCA2 ORF Clone (NM_001044775) | Inquiry |
| CDCH083402 | Mouse Smarca2 ORF clone (NM_026003.2) | Inquiry |
| CDCB167114 | Chicken SMARCA2 ORF Clone (NM_205139) | Inquiry |
The SMARCA2 gene, also known as BRM, is located on human chromosome 9p24.3 and encodes one of the highly conserved catalytic subunits of the SWI/SNF chromatin remodeling complex. The encoded protein belongs to the SNF2-like helicase superfamily, featuring a central DExH domain with ATP hydrolysis activity and a C-terminal bromodomain. The bromodomain functions as a key "epigenetic reader," specifically recognizing and binding acetylated lysine residues on histone tails, a core mechanism for translating chromatin modification states into defined gene expression programs. SMARCA2, together with its closely related paralog SMARCA4, represents the two primary ATPase motors in mammalian cells, driving SWI/SNF-mediated chromatin remodeling activity. Notably, the SMARCA2 gene contains a polymorphic trinucleotide repeat, whose biological significance remains under investigation. Through complex alternative splicing, SMARCA2 can generate multiple protein isoforms with potentially subtle functional differences, further increasing its regulatory complexity and precision in gene networks.
Figure 1. Domain organization of SMARCA2, shown in a 3D model and a bar-like representation. (Guo Z, et al., 2025)
SMARCA2's biological importance lies in its role as a central engine of chromatin remodeling. The SWI/SNF complex harnesses the energy from SMARCA2-mediated ATP hydrolysis to systematically alter DNA-histone contacts within nucleosomes, dynamically regulating chromatin structure and accessibility without changing the underlying DNA sequence. This remodeling activity can shift tightly packed, transcriptionally repressive chromatin into a relaxed, transcriptionally permissive state and vice versa, allowing SMARCA2 to function as either a transcriptional activator or repressor depending on context. This dual functionality is critical for maintaining cell identity, regulating the cell cycle, and determining cell fate.
During neural development, SMARCA2 plays a particularly nuanced role. It is incorporated into neural progenitor-specific (npBAF) and neuron-specific (nBAF) chromatin remodeling complexes. At key developmental transitions, as neural progenitor cells exit the cell cycle and differentiate into mature post-mitotic neurons, specific subunits in the npBAF complex are replaced by homologous subunits in the nBAF complex. SMARCA2 remains present throughout this transition, but its functional output depends on the complex context. The npBAF complex is essential for maintaining self-renewal and proliferative capacity in multipotent neural stem cells, whereas the nBAF complex collaborates with proteins such as CREST to activate gene programs critical for dendritic growth and neuronal morphology, thereby establishing the anatomical basis for neural network connectivity. Furthermore, loss or dysfunction of SMARCA2 expression is closely linked to uncontrolled cell proliferation, and its potential role as a tumor suppressor is increasingly recognized across multiple cancers.
Clinically, SMARCA2 is relevant in cancer and neurodevelopmental disorders. In oncology, SMARCA2 is mutated or downregulated in several malignancies, including lung cancer, lymphoma, and hepatocellular carcinoma. Loss of function may promote tumorigenesis by impairing the activation of tumor suppressor genes mediated by chromatin remodeling. A more translationally promising discovery is the "addiction" of SMARCA4-deficient cancers to SMARCA2 function. SMARCA4, SMARCA2's closest paralog, is frequently mutated in many cancers. When SMARCA4 function is lost, SMARCA2 becomes the essential alternative ATPase for maintaining cell survival and proliferation. This synthetic lethality provides a precise therapeutic target, and the development of potent, selective SMARCA2 bromodomain inhibitors has become a focus in anticancer drug discovery. These small molecules competitively occupy the acetyl-lysine binding pocket of SMARCA2, disrupting its chromatin binding and remodeling functions, selectively inducing growth arrest and apoptosis in SMARCA4-deficient cancer cells while sparing cells with functional SMARCA4.
Beyond cancer, SMARCA2 dysfunction is also associated with certain neurodevelopmental disorders, although the mechanisms are less well defined. Given its critical role in neuronal differentiation and dendritic development, SMARCA2 single nucleotide polymorphisms or rare variants may contribute to individual susceptibility to neuropsychiatric conditions. Overall, as a hub connecting epigenetic regulation with core cellular functions, SMARCA2 represents a clinically valuable target, and synthetic lethality-based therapeutic strategies offer a promising avenue for precision oncology.
References